Exenatide: Treatment of Type 2 Diabetes
EIi Lilly and Company and Amylin Pharmaceuticals, Inc. recently announced that the European Commission has granted marketing authorization for Byetta (exenatide) for the treatment of type 2 diabetes. Exenatide is now approved in the European Union as adjunctive therapy to improve blood sugar control in patients with type 2 diabetes who have not achieved adequate […]